EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)
← catalyst calendarNCT06808880 · readout ≤ 254 d
Sponsored by Natera, Inc. (industry) · NTRA — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
4,000estimated
Sites
18
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-01-25 | actual | When the study began enrolling |
| Primary completion | Apr 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Single Gene NIPT
Intervention
- Device: Single-gene Noninvasive Prenatal Testing (sgNIPT)
Primary outcome
what the primary-completion date above is the date OFPerformance of sgNIPT assay in the detection of primary four autosomal recessive disorders
measured Following the development of the sgNIPT assay, approximately 2 years after the launch of the study
Permalink · NTRA's whole pipeline · Catalyst calendar · Every registered study · What changed